Almirall signs license agreement with Sun Pharma for Tildrakizumab in Europe for psoriasis
First IL-23p19 antibody to meet primary endpoints in pivotal phase-3 clinical trials in patients with moderate-to-severe plaque…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.